morphine

(redirected from Avinza)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • noun

Synonyms for morphine

an alkaloid narcotic drug extracted from opium

References in periodicals archive ?
The safety profiles of Avinza and MS Contin were similar.
The sleep benefits from Avinza were seen with relatively low doses.
Actavis filed its ANDA for Avinza containing the paragraph IV certification with the U.
In addition, there can be no assurance that Ligand will achieve its guidance for 2010 or 2011, that Ligand will deliver strong cash flow over the long-term, that Ligand's 2010 or 2011 revenues will be driven by royalty payments related to AVINZA and PROMACTA sales, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval in 2010 or later, or that there will be a market for such product(s) if successfully developed and approved.
Moreover, products like Skelaxin, Avinza and EpiPen are all facing patent challenges.
In addition, there can be no assurance that Ligand will achieve its guidance for 2010, that Ligand will deliver strong cash flow over the long-term, that Ligand's 2010 revenues will be driven by royalty payments related to AVINZA and PROMACTA sales, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval in 2010 or later, or that there will be a market for such product(s) if successfully developed and approved.
Approved by the FDA in March 2002, AVINZA consists of two components: an immediate-release component that rapidly achieves plateau morphine concentrations in plasma, and an extended-release component that maintains plasma concentrations throughout a 24-hour dosing interval.
For example, we may not receive expected royalties on AVINZA from King Pharmaceuticals, PROMACTA from GSK or any other partnered products or from research and development milestones, and we may not be able to timely or successfully advance any product(s) in Ligand's pipeline.
The Complaint alleges that Ligand, pharmaceutical company that discovers, develops and markets drugs, and certain of its officers and directors failed to disclose that inventory de-stocking at the wholesale level was occurring because the Company was unloading Avinza inventory which was about to expire, that the overall demand of the Company's products was down due to inventory de-stocking, and that Medicaid prescriptions were increasing, causing the Company to pay large rebates to Medicaid and that in fact the increase in rebates was not a one-time occurrence.
0 million of non-cash deferred revenue, royalty payments from sales of AVINZA and PROMACTA, revenue from collaboration agreements and potential milestone payments from existing corporate partners.
The complaint alleges that the Defendants failed to disclose and/or misrepresented that inventory de-stocking at the wholesale level was occurring because the Company was unloading Avinza inventory which was about to expire, that the overall demand of the Company's products was down due to inventory de-stocking, and that Medicaid prescriptions were increasing, causing the Company to pay large rebates to Medicaid and that in fact the increase in rebates was not a one-time occurrence.